Background: Effective contraception reduces unintended pregnancies and is a central strategy to reduce vertical HIV-1 transmission for HIV-1-infected women.
Introduction
Pregnancy rates are high in sub-Saharan Africa [1] and almost one-quarter of pregnancies are estimated to be unintended [2] . Reducing unintended pregnancies among HIV-1-seropositive women is a core strategy to reduce vertical HIV-1 transmission [3] . Moreover, pregnancy may increase HIV-1 risk, further emphasizing the benefits of preventing unintended pregnancies [4, 5] .
For clinical trials of new HIV-1 prevention strategies, such as antiretroviral preexposure prophylaxis, contraceptive use minimizes protocol-required discontinuation of study products during pregnancy and fetal exposure to investigational agents [6] . Indeed, some recent HIV-1 prevention trials have required participants to use an effective contraceptive method in order to qualify for enrollment [7] .
In previous studies among women from Africa, factors related to incident pregnancy have included younger age, fewer children, cohabitation with a male partner and having frequent sex unprotected by condoms [8, 9] . Few studies have explored whether the choice of contraceptive method impacts pregnancy incidence among HIV-1-seropositive and HIV-1-seronegative African women. Among women participating in an HIV-1 prevention trial, all of whom were in an HIV-1serodiscordant partnership (i.e. one partner was HIV-1 infected and the other was HIV-1 uninfected), we sought to determine if pregnancy incidence differed by contraceptive method.
Methods

Population and procedures
Between December 2004 and October 2008, 3408 heterosexual HIV-1-serodiscordant couples were enrolled in the Partners in Prevention HSV/HIV Transmission Study, a randomized, double-blind, placebo-controlled clinical trial of daily acyclovir herpes simplex virus type 2 (HSV-2) suppressive therapy provided to HIV-1-seropositive members of couples to reduce HIV-1 transmission risk. The study was conducted at 14 sites in seven countries in eastern and southern Africa (Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda and Zambia); acyclovir did not decrease HIV-1 transmission risk [10] . Couples were recruited through community outreach activities and referrals from HIV-1 testing and care organizations [11] . This report is a secondary analysis using data from this prospective study.
Eligible couples were at least 18 years of age, reported more than three episodes of vaginal intercourse during the 3 months prior to screening, and intended to remain as a couple. HIV-1-infected partners were seropositive for HSV-2, had a CD4 count of at least 250 cells/ml and were not eligible at enrolment for antiretroviral therapy (ART), according to national guidelines. Couples were followed for up to 24 months, with HIV-1 seropositive partners seen monthly and HIV-1 seronegative partners seen quarterly and were encouraged to come together during the quarterly visit for couples' risk reduction counseling. HIV-1-infected partners who became eligible for ART initiation during follow-up were actively referred to local HIV-1 care clinics.
Women were not required to use contraception, although HIV-1 seropositive women (who received study medication) could not be pregnant at study enrollment and were encouraged to delay pregnancy until after the study. Current contraceptive method, by self-report, was recorded at each study visit. Contraception was provided on-site or by referral [12] . For hormonal contraceptive methods, specific brand names were not recorded, although combined low-dose oral contraceptives and injectable depot medroxyprogesterone acetate were the most common contraceptive types used in national family planning programs at the time of the study. Urine pregnancy tests were performed quarterly for HIV-1seropositive women; for HIV-1-seronegative women, pregnancy tests were done based on report of missed menses. HIV-1 seropositive women who became pregnant discontinued study medication for the duration of pregnancy and were referred for prevention of motherto-child HIV-1 transmission services, and HIV-1seronegative women who became pregnant were referred for antenatal services. All participants provided written informed consent. The institutional review boards at the University of Washington and all study sites approved the study protocol.
Statistical methods
We used multivariate Andersen-Gill modeling for recurrent events (with Efron methods for ties [13] ) to assess the risk of pregnancy among women using different contraceptive methods versus women not using any contraception, analyzed as a time-dependent variable. Adjusted models included socio-demographic and clinical factors. Observations following pregnancy discovery at the study site were censored; observations following pregnancy termination remained in the dataset, as women returned to being 'at risk' for another pregnancy. For women experiencing multiple pregnancies, the same censoring rules were used for observations during the second or third pregnancy. For HIV-1seronegative women, observations were censored following HIV-1 seroconversion. We tested whether the effectiveness of each contraceptive method differed between HIV-1-seropositive and HIV-1-seronegative women using a likelihood ratio test. Analyses were conducted using SAS 9.2 (SAS Institute, Cary, North Carolina, USA). 
Contraceptive use and pregnancy during followup
Of the participants, 83.3 and 80.5% of HIV-1seropositive and HIV-1-seronegative women reported using condoms as contraceptive method at least once during the study, 12.6 and 9.0% ever used oral contraceptives and 33.0 and 20.3% ever used injectable contraception. However, 67.0% of HIV-1-seropositive and 63.5% of HIV-1-seronegative women reported no contraceptive method during at least 1 study visit.
Among women not using contraception, pregnancy incidence was 21.0 and 26.8 per 100 woman-years for HIV-1-seropositive and HIV-1-seronegative women ( Table 2) . Pregnancy rates were lower among women using condoms only (18.4 and 11.4 per 100 woman-years for seropositive and seronegative women, respectively), oral contraception (15.6 and 14.4 per 100 woman-years), and injectable contraception (6.8 and 6.0 per 100 woman-years). There were no pregnancies observed among women using intrauterine devices (IUDs), implantable methods or who had undergone surgical sterilization, but very few women used these methods.
In multivariate analysis, both HIV-1-seropositive and HIV-1-seronegative women were substantially less likely to become pregnant if they used injectable contraception compared to women who used no contraception [adjusted hazard ratio (aHR) 0.25, P < 0.001 and aHR 0.24, P ¼ 0.001, respectively). Condoms and oral contraceptives also reduced the incidence of pregnancy, but the effect of oral contraceptives was not statistically different from the effect of no contraception among HIV-1seronegative women (aHR 0.64, P ¼ 0.3) and the effect of condoms was not statistically different from the effect of no contraception among HIV-1-seropositive women (aHR 0.85, P ¼ 0.1). The extent to which condoms prevented pregnancy among HIV-1-seropositive (aHR Contraceptive methods and pregnancy Ngure et al. 515 Table 1 . Participant characteristics a . 0.85, P ¼ 0.1) and HIV-1-seronegative women (aHR 0.67, P ¼ 0.02) was statistically different (P value for interaction¼0.002), but the effectiveness of injectables and oral contraceptives was not different (P value for interaction¼0.15 and 0.1, respectively). When compared with those using injectable contraception, women were more likely to become pregnant if they used oral contraceptives (aHR 2.06, P ¼ 0.01 for HIV-1-seropositive women and aHR 2.71, P ¼ 0.09 for HIV-1seronegative women) or condoms only (aHR 3.39, P < 0.001 for HIV-1-seropositive women and aHR 2.82, P ¼ 0.01 for HIV-1-seronegative women).
HIV
In the multivariate models, other factors independently associated with incident pregnancy included being younger (aHR 5.08, P < 0.001 for HIV-1-seropositive women and aHR 4.48, P < 0.001 for HIV-1-seronegative women for those 24 years of age and aHR 3.16, P < 0.001 and aHR 3.16, P < 0.001 for those 25-34 years when compared with women >35 years old), having at least two children (aHR 1.96, P < 0.001 and aHR 2.49, P ¼ 0.001), having a greater number of sex acts (aHR 1.81-2.32 for categories >0/month as defined in footnote to Table 2 ; not statistically significant for HIV-1-seronegative women), reporting unprotected sex with the study partner (independent of condom use for contraception, aHR 2.30, P < 0.001 and aHR 5.89, P < 0.001) and having sex with a partner other than the study partner (aHR 2.24, P < 0.001 and aHR 3.26, P < 0.001). Having a curable sexually transmitted infection at the time of study enrollment and ART use by the HIV-1-seropositive member of the couple during study follow-up were not associated with pregnancy.
Discussion
In this large, prospective, multinational cohort of HIV-1seropositive and HIV-1-seronegative African women in known heterosexual HIV-1 serodiscordant partnerships, women using injectable contraceptives had significantly lower pregnancy rates than oral contraceptive users. These results are consistent with previous studies reporting that injectable methods are more effective than oral methods in reducing the likelihood of pregnancy [8, 9, 14] . We also observed high rates of pregnancy for both HIV-1-seropositive and HIV-1seronegative women (incidence 15.6 and 14.8 per 100 woman-years, respectively) -similar to rates seen in other HIV-1 prevention trials in sub-Saharan Africa [8, 9, 15] . These high rates of pregnancy have the potential to compromise the power of biomedical HIV-1 prevention trials involving women, as those who become pregnant often are required to discontinue study products.
Notably, we found that no women using IUDs and implantable contraceptives experienced pregnancy, although the number using these methods was small. Previous studies have reported that IUDs are well tolerated and effective for preventing pregnancy among women with and at risk for HIV-1, yet their use is still very low in sub-Saharan Africa [16] [17] [18] . Our data provide additional evidence of the potential for well tolerated and effective long-acting user-independent contraceptive methods to reduce unintended pregnancies among HIV-1-seronegative and HIV-1-seropositive African women.
We have previously reported higher rates of condom use and lower rates of incident HIV-1 infection in this cohort 516 AIDS 2012, Vol 26 No 4 Multivariate Andersen-Gill proportional hazards analysis, adjusted for age (24, 25-34 and 35 years), number of children with study partner (0, 1 and 2), partnership duration (<1, 1-3, 4-10 and >10 years), number of sex acts (0, 1-5, 6-10 and >10 per month), any unprotected sex with study partner (any versus none, per month), any sex with additional partners (any versus none, per month), having a sexually transmitted infection at study enrolment (any of Neisseria gonorrhoeae, Chlamydia trachomatis or Trichomonas vaginalis in either partner) and antiretroviral therapy use by the HIV-1-seropositive member of the couple.
(2.7 cases per 100 person-years overall) [10] compared with similar cohorts in this geographical region [19, 20] . In our cohort, condoms alone were not as effective for pregnancy prevention as injectable methods and their effectiveness differed based on HIV-1 status. Qualitative work we have done among HIV-1-serodiscordant couples has described challenges with consistent and correct condom use, with seronegative women reported more consistent condom use to prevent HIV-1 acquisition than seronegative men [21] . As family planning programs consider novel ways to increase access to and uptake of long-acting user-independent methods, it is also important to continue counseling women and men about the importance of condom use for protection against HIV-1 and sexually transmitted infections in conjunction with hormonal contraceptive use for pregnancy prevention [22, 23] . In clinical trial settings, efforts to link participants with contraceptive counseling and resources in the community will foster sustained use of contraceptive methods following study closure.
In conclusion, in this study of more than 3300 African women in stable heterosexual partnerships, injectable methods were the most effective contraceptive method for pregnancy prevention. Family planning programs and HIV-1 prevention trials need to develop innovative ways to motivate use of longer-acting, less user-dependent contraception for women with or at risk of HIV-1 who do not desire pregnancy and ensure that couples understand the importance of using dual methods for HIV-1 and pregnancy prevention.
